Recently, the Narlumosbart Injection (Chinese trade name: 津立生) of Shanghai JMT Biological Technology Co. Ltd. is approved with conditions through the priority review and approval procedure by China NMPA. This drug is indicated for the treatment for adult patients with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

The Narlumosbart Injection is a recombinant human anti-receptor activator of NF-κB ligand (RANKL) monoclonal antibody. It can inhibit the activity of RANKL through specifically binding to RANKL on the cell membrane, thereby inhibiting its involvement in mediating osteolysis and tumor growth. The marketing of this drug provides a new treatment option for patients.